Figure 2From: Initial clinical trial of epratuzumab (humanized anti-CD22 antibody) for immunotherapy of systemic lupus erythematosusOverall frequency and mean improvement of total disease activity as measured by the total BILAG score at 6, 10 and 18 weeks.Back to article page